EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Healthcare resource utilization and costs in immunodeficient patients receiving subcutaneous Ig: Real-world evidence from France

Guillaume Lefèvre, Isabelle Borget, Cinira Lefèvre iD, Chahrazed Maherzi, Arnaud Nucit, Mouna Hennaoui, Aurélie Schmidt, Hannah Lennon, Benjamin Grenier iD, Florent Daydé iD, Nizar Mahlaoui

PLOS ONE · 2025

DOI: 10.1371/journal.pone.0313694 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2025. Verfasst von Guillaume Lefèvre und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Immunology, Institute for Translational Research in Inflammation (Infinite - U1286), University of Lille, CHU Lille, Inserm, Lille, Fran…. Hauptthemen laut MEDLINE: Health Care Costs, Patient Acceptance of Health Care, Immunologic Deficiency Syndromes, Immunoglobulins. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Pharmaceuticals International.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Subcutaneous immunoglobulin (SCIg) replacement therapy is indicated for patients with hypogammaglobulinemia caused by primary (PID) and secondary immunodeficiencies (SID).

Objective

To compare healthcare resource utilization (HCRU) and related direct medical costs of patients in France treated with weekly conventional SCIg (cSCIg) vs monthly hyaluronidase-facilitated SCIg (fSCIg).

Methods

This retrospective study of Ig-naïve patients with PID or SID newly receiving a SCIg between 2016 and 2018, extracted from the French National Healthcare reimbursement database (SNDS), analyzed the SCIg-related HCRU and reimbursed costs generated from in-hospital (hospitalizations and SCIg doses) or at-home (nurse visits [NV] and pump provider visits [PPV], drug doses) SCIg administration.

Results

Overall, 2,012 patients (PID:534; SID:1,478) were analyzed. The follow-up duration varied between 7.5 and 8.7 months according to sub-groups. Compared with fSCIg-treated patients, monthly mean rates of NV and PPV were respectively 2.5 and 3.1 times higher in PID, and 1.6 and 3.1 times higher in SID cSCIg-treated patients. Monthly mean rates for SCIg administration-related hospitalizations were lower overall, while their costs were 1.6 and 1.8 times higher for cSCIg than fSCIg subgroups, in PIDs and SIDs respectively; these results are due to more frequent hospitalizations with fSCIg being mainly shorter, without stayover. Total HCRU costs from the French NHI’s perspective were estimated to be lower with fSCIg vs cSCIg, in PIDs and SIDs.

Conclusion

This study provides real-world evidence of SCIg administration in a large French population. Patients with PID or SID treated with fSCIg had fewer at-home HCRU and lower overall costs for in-hospital or at-home SCIg administration compared with cSCIg-treated patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Health Care CostsPatient Acceptance of Health CareImmunologic Deficiency SyndromesImmunoglobulinsHumansFranceFemaleMaleRetrospective StudiesAdultMiddle AgedAdolescentChild, PreschoolChildInfantYoung AdultHospitalizationHealth ResourcesAged

Substanzen

Immunoglobulins

Autor:innen und Institutionen

  • Institute of Immunology, Institute for Translational Research in Inflammation (Infinite - U1286), University of Lille, CHU Lille, Inserm, Lille, France.
  • Department of Biostatistics and Epidemiology, Gustave Roussy, Paris-Saclay University, Gif-sur-Yvette, Villejuif, France.
  • Oncostat - U1018, Inserm, Paris-Saclay University, "Ligue Contre le Cancer" Labeled Team, Gif-sur-Yvette, Villejuif, France.
  • GRADES, Paris-Saclay University, Gif-sur-Yvette, Châtenay-Malabry, France.
  • Takeda France, Paris, France.
  • HEVA, Lyon, France.

ORCID-Profile: Cinira Lefèvre, Benjamin Grenier, Florent Daydé

Förderung

  • Takeda Pharmaceuticals International

Zitieren

APA

Lefèvre, G., Borget, I., Lefèvre, C., Maherzi, C., Nucit, A., Hennaoui, M., Schmidt, A., Lennon, H., Grenier, B., Daydé, F., & Mahlaoui, N. (2025). Healthcare resource utilization and costs in immunodeficient patients receiving subcutaneous Ig: Real-world evidence from France. PLOS ONE. https://doi.org/10.1371/journal.pone.0313694

Vancouver

Lefèvre G, Borget I, Lefèvre C, Maherzi C, Nucit A, Hennaoui M, et al. Healthcare resource utilization and costs in immunodeficient patients receiving subcutaneous Ig: Real-world evidence from France. PLOS ONE. 2025. doi:10.1371/journal.pone.0313694

BibTeX
@article{Lefvre2025,
  author = {Lefèvre, Guillaume and Borget, Isabelle and Lefèvre, Cinira and Maherzi, Chahrazed and Nucit, Arnaud and Hennaoui, Mouna and Schmidt, Aurélie and Lennon, Hannah and Grenier, Benjamin and Daydé, Florent and Mahlaoui, Nizar},
  title = {Healthcare resource utilization and costs in immunodeficient patients receiving subcutaneous Ig: Real-world evidence from France},
  journal = {PLOS ONE},
  year = {2025},
  doi = {10.1371/journal.pone.0313694}
}
Kostenlos starten →